SUCLG1 Antibody

What is SUCLG1 and why is it important in cellular metabolism?

SUCLG1 (Succinate-CoA ligase GDP-forming subunit 1) is an enzyme that functions in the tricarboxylic acid (TCA) cycle, catalyzing the conversion of succinyl-CoA to succinate. This reaction represents the only step of substrate-level phosphorylation in the TCA cycle, coupling the hydrolysis of succinyl-CoA to the synthesis of either ATP or GTP . The protein is highly expressed in metabolically active tissues such as the liver, kidney, and brain where energy demand is significant . Recent research has demonstrated that SUCLG1 plays a crucial role in regulating mitochondrial biogenesis and function through controlling succinyl-CoA levels and subsequently affecting post-translational modifications of key mitochondrial proteins .

What are the structural characteristics and cellular localization of SUCLG1?

SUCLG1 is the alpha subunit of succinate-CoA ligase and forms a heterodimer with SUCLG2 (the beta subunit) to create the functional enzyme complex . The protein has a calculated molecular weight of approximately 35-36 kDa and contains a 40 amino acid transit peptide that directs it to mitochondria . Immunofluorescence studies using SUCLG1 antibodies have confirmed its mitochondrial localization. For example, confocal immunofluorescent analysis of HeLa cells using SUCLG1 antibody (GTX109215) demonstrated clear mitochondrial staining . The alpha subunit specifically binds the substrates coenzyme A and phosphate, while succinate binding and specificity for either ATP or GTP is provided by different beta subunits .

How do SUCLG1 antibodies differ in their epitopes and applications?

Different commercial SUCLG1 antibodies target various epitopes within the protein, which can affect their utility in different applications. For example:

The choice of antibody should be guided by the specific application, species of interest, and the domain of SUCLG1 relevant to your research question .

What are the optimal conditions for using SUCLG1 antibodies in Western blot applications?

For Western blot applications, SUCLG1 antibodies typically perform optimally under the following conditions:

• Sample preparation: Total cell lysates or mitochondrial fractions can be used. Various whole cell extracts (30 μg) separated by 10% SDS-PAGE have been successfully used .

• Dilution ranges:

  • Proteintech 14923-1-AP: 1:5000-1:10000

  • GeneTex GTX109215: 1:1000

  • Abcam ab97867: 1:1000

  • Sigma HPA036683: 0.04-0.4 μg/mL

• Expected band size: Approximately 35-36 kDa, consistent with the calculated molecular weight of SUCLG1 .

• Positive controls: HepG2 cells, rat liver tissue, A431 whole cell lysate, U-251 MG, and RT4 lysates have been validated as positive controls for SUCLG1 detection .

• Detection method: Standard HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) detection systems are suitable for visualizing SUCLG1 bands.

When comparing results across different cell types or treatments, it is advisable to use loading controls such as β-actin or GAPDH for cytoplasmic normalization, or mitochondrial proteins like COX IV for mitochondrial fraction normalization .

How can SUCLG1 antibodies be utilized for investigating mitochondrial dynamics and function?

SUCLG1 antibodies serve as valuable tools for studying mitochondrial dynamics and function through several methodological approaches:

• Co-localization studies: Dual immunofluorescence staining with SUCLG1 antibodies and other mitochondrial markers (e.g., MitoTracker) can reveal changes in mitochondrial morphology and distribution. SUCLG1 antibodies like GTX109215 have been validated for confocal immunofluorescent analysis showing clear mitochondrial localization .

• Protein-protein interaction analysis: Immunoprecipitation using SUCLG1 antibodies can identify interaction partners within mitochondrial pathways. Recent research has demonstrated that SUCLG1 interacts with mitochondrial RNA polymerase (POLRMT) and mitochondrial transcription factors, suggesting a role in regulating mtDNA transcription .

• Post-translational modification studies: SUCLG1 affects protein succinylation levels, particularly of POLRMT. Antibodies against SUCLG1 can be used alongside succinylation-specific antibodies to investigate this regulatory mechanism .

• Mitochondrial biogenesis assessment: Knockdown or overexpression of SUCLG1 followed by immunoblotting for mitochondrial markers provides insights into its role in mitochondrial biogenesis. Research has shown that SUCLG1 depletion decreases mitochondrial mass and mtDNA abundance .

• Metabolic profiling: Combining SUCLG1 antibody-based techniques with metabolomic analyses can reveal the metabolic consequences of altered SUCLG1 expression, particularly regarding TCA cycle intermediates like succinyl-CoA and succinate .

What are the recommended protocols for immunohistochemistry using SUCLG1 antibodies?

For successful immunohistochemistry (IHC) with SUCLG1 antibodies, the following protocol elements are recommended:

• Tissue preparation: Both paraffin-embedded and frozen sections can be used, depending on the antibody. For paraffin sections, standard fixation with 10% neutral buffered formalin is suitable .

• Antigen retrieval:

  • Heat-mediated antigen retrieval with citrate buffer pH 6.0 works well for many SUCLG1 antibodies .

  • Some antibodies perform better with TE buffer pH 9.0, as recommended for Proteintech 14923-1-AP .

• Antibody dilutions:

  • Sigma HPA036683: 1:1000-1:2500

  • Proteintech 14923-1-AP: 1:50-1:500

• Detection systems: Standard avidin-biotin complex (ABC) or polymer-based detection systems are suitable.

• Positive control tissues: Human cerebellum, mouse kidney tissue, and human liver cancer tissue have been validated as positive controls for SUCLG1 IHC .

• Counterstaining: Hematoxylin counterstaining provides good nuclear contrast against the cytoplasmic/mitochondrial SUCLG1 staining.

Tissue-specific optimization may be necessary, as SUCLG1 expression varies across different tissues, with higher expression in metabolically active tissues such as liver, kidney, and brain .

How can SUCLG1 antibodies be used to investigate the relationship between metabolic alterations and cancer progression?

Recent research has revealed a significant connection between SUCLG1, metabolism, and cancer development, particularly in leukemia. SUCLG1 antibodies can be employed in several advanced research approaches to investigate these relationships:

• Correlation analysis of SUCLG1 with ETC genes: SUCLG1 expression strongly correlates with electron transport chain (ETC) gene expression across various cancers. Researchers can use SUCLG1 antibodies in combination with antibodies against ETC components to validate transcriptomic findings at the protein level .

• Mechanistic studies of POLRMT regulation: SUCLG1 restricts succinyl-CoA levels to suppress the succinylation of mitochondrial RNA polymerase (POLRMT). Using SUCLG1 antibodies for co-immunoprecipitation with POLRMT, followed by analysis with succinylation-specific antibodies, can reveal how this post-translational modification affects mitochondrial transcription in cancer cells .

• Metabolite-protein interaction studies: By combining SUCLG1 antibody-based techniques with metabolomic profiling, researchers can investigate how altered levels of TCA cycle intermediates (particularly succinyl-CoA and succinate) affect protein modifications and cellular signaling in cancer cells .

• Therapeutic target validation: In leukemia models, genetic depletion of SUCLG1 significantly delays disease progression. SUCLG1 antibodies can be used to monitor protein expression changes in response to potential therapeutic interventions targeting this pathway .

• Analysis of FLT3 mutation effects: In AML with FLT3 mutations, SUCLG1 expression is upregulated, leading to enhanced mitobiogenesis. SUCLG1 antibodies can help validate this regulatory axis and identify potential therapeutic vulnerabilities .

What are the best practices for analyzing SUCLG1 expression in relation to mitochondrial dysfunction in disease models?

When investigating SUCLG1 expression in relation to mitochondrial dysfunction in disease models, consider these methodological approaches:

• Multi-parameter analysis: Combine SUCLG1 antibody staining with functional mitochondrial assays:

  • Oxygen consumption rate (OCR) measurements

  • Mitochondrial membrane potential assessment

  • mtDNA copy number quantification

  • ATP production assays

• Tissue-specific considerations: SUCLG1 expression varies across tissues, with highest expression in metabolically active organs. When comparing disease states, ensure appropriate tissue-matched controls are used .

• Subcellular fractionation protocols: For accurate assessment of mitochondrial SUCLG1 levels:

  • Use established mitochondrial isolation protocols with appropriate buffers

  • Verify fraction purity using markers for mitochondria (VDAC, COX IV), cytoplasm (GAPDH), and other organelles

  • Normalize SUCLG1 levels to mitochondrial mass markers

• Genetic models: In SUCLG1-knockdown or knockout models, validate the degree of protein reduction using antibodies and confirm specificity of the phenotype through rescue experiments with wild-type SUCLG1 but not catalytically inactive mutants .

• Patient sample analysis: When analyzing patient samples with suspected SUCLG1 deficiency:

  • Compare enzyme activity assays with protein expression levels

  • Consider post-translational modifications that might affect function without altering expression

  • Correlate findings with clinical phenotypes and metabolite profiles

How can researchers distinguish between different SUCLG1 complexes using antibody-based approaches?

SUCLG1 can form complexes with different beta subunits (SUCLG2 for GTP-forming activity or SUCLA2 for ATP-forming activity). Distinguishing between these complexes requires sophisticated antibody-based approaches:

• Sequential immunoprecipitation:

  • First immunoprecipitate with SUCLG1 antibody

  • Then probe the immunoprecipitate with antibodies against SUCLG2 or SUCLA2 to determine complex composition

  • Alternatively, perform the initial IP with SUCLG2 or SUCLA2 antibodies and then probe for SUCLG1

• Blue native PAGE analysis:

  • Preserve native protein complexes using non-denaturing conditions

  • Separate complexes based on size

  • Perform western blotting with SUCLG1 antibodies

  • The different migration patterns can identify distinct SUCLG1-containing complexes

• Proximity ligation assay (PLA):

  • Use SUCLG1 antibody in combination with either SUCLG2 or SUCLA2 antibodies

  • Generate fluorescent signals only when proteins are in close proximity (<40 nm)

  • Quantify the fluorescent dots to assess relative abundance of different complexes

• Size exclusion chromatography followed by immunoblotting:

  • Separate protein complexes based on size

  • Analyze fractions by western blot using SUCLG1, SUCLG2, and SUCLA2 antibodies

  • Compare elution profiles to identify different complexes

What are common issues encountered when using SUCLG1 antibodies and how can they be resolved?

Researchers working with SUCLG1 antibodies may encounter several technical challenges. Here are common issues and their solutions:

• High background in Western blots:

  • Increase blocking time (use 5% BSA or milk in TBST)

  • Optimize antibody dilution (start with manufacturer recommendations and titrate if needed)

  • Include additional washing steps (4-5 washes, 5-10 minutes each)

  • For polyclonal antibodies like GTX109215 or ab97867, try increasing the dilution factor

• Weak or absent signal in immunohistochemistry:

  • Optimize antigen retrieval methods (try both citrate buffer pH 6.0 and TE buffer pH 9.0)

  • Use more concentrated antibody dilutions (1:50-1:100 for initial tests)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Consider signal amplification systems (tyramide signal amplification)

  • Use positive control tissues known to express SUCLG1 (liver, kidney, brain)

• Multiple bands in Western blot:

  • Verify sample preparation (include protease inhibitors)

  • Check for post-translational modifications or isoforms

  • Optimize gel percentage (10% SDS-PAGE is commonly used)

  • Use freshly prepared samples to minimize degradation

  • Consider pre-absorbing antibody with recombinant SUCLG1 to test specificity

• Poor reproducibility:

  • Standardize protein extraction and quantification methods

  • Maintain consistent sample loading (30 μg is typically used)

  • Use internal loading controls for normalization

  • Document lot numbers of antibodies, as different lots may show variation

How should researchers approach validation of SUCLG1 knockdown or knockout models using antibodies?

Proper validation of SUCLG1 knockdown or knockout models is essential for meaningful research. A comprehensive approach includes:

• Multi-antibody validation:

  • Use at least two different SUCLG1 antibodies targeting different epitopes

  • Compare results from antibodies like CAB15345 (targeting aa 41-346) and ab204432 (targeting aa 100-200)

  • Ensure consistent results across different antibodies to rule out non-specific binding

• Quantitative assessment:

  • Perform densitometric analysis of Western blots

  • Normalize to appropriate loading controls

  • Report the percentage of knockdown/knockout achieved

  • Use positive controls (wild-type cells) and negative controls (known SUCLG1-deficient cells if available)

• Functional validation:

  • Measure succinate-CoA ligase enzyme activity in cell extracts

  • Assess by LC-MS/MS enzyme activity assay using both ATP and GTP as substrates

  • Correlate protein levels with enzyme activity

• Rescue experiments:

  • Re-express wild-type SUCLG1 in knockdown/knockout cells

  • Include catalytically inactive mutants as controls

  • Demonstrate restoration of both protein expression and functional phenotypes

  • Use lentiviral transduction systems as described in the literature

• Metabolic consequences:

  • Measure TCA cycle intermediates, particularly succinyl-CoA and succinate

  • Assess mitochondrial parameters (mtDNA copy number, oxygen consumption)

  • These metabolic changes should correlate with SUCLG1 protein levels

What considerations are important when using SUCLG1 antibodies for studying post-translational modifications?

When investigating post-translational modifications (PTMs) of SUCLG1 or how SUCLG1 affects PTMs of other proteins, several methodological considerations are critical:

• Sample preparation for preserving PTMs:

  • Include appropriate inhibitors (phosphatase inhibitors for phosphorylation studies)

  • For succinylation studies, include deacetylase inhibitors like nicotinamide and trichostatin A

  • Use fresh samples when possible, as PTMs can be lost during storage

• PTM-specific antibodies in combination with SUCLG1 antibodies:

  • For studying POLRMT succinylation, use anti-succinyl-lysine antibodies after immunoprecipitation with POLRMT antibodies

  • Compare results in SUCLG1-normal versus SUCLG1-depleted conditions

• Mass spectrometry validation:

  • After immunoprecipitation with SUCLG1 antibodies, perform mass spectrometry

  • Map specific PTM sites and quantify modification levels

  • Validate key findings with site-specific antibodies if available

• Controls for PTM specificity:

  • Include controls for other similar PTMs (e.g., acetylation when studying succinylation)

  • Use appropriate enzymes that remove specific PTMs as negative controls

  • Include both positive and negative controls for PTM antibodies

• Functional consequences of PTMs:

  • Design experiments to test how identified PTMs affect protein function

  • For SUCLG1-regulated succinylation of POLRMT, assess effects on mtDNA binding and transcriptional activity

  • Create site-specific mutants that either prevent or mimic the PTM to validate functional significance

How does the recent discovery of SUCLG1's role in regulating POLRMT succinylation impact research approaches?

The discovery that SUCLG1 restricts succinyl-CoA levels to suppress the succinylation of mitochondrial RNA polymerase (POLRMT) has significant implications for research approaches:

• Integrated metabolite-protein modification studies: This finding necessitates research designs that simultaneously monitor metabolite levels (particularly succinyl-CoA) and protein post-translational modifications. Researchers should now include metabolomic analyses alongside proteomic approaches when studying SUCLG1 .

• Focus on lysine 622 of POLRMT: Lysine 622 succinylation disrupts the interaction of POLRMT with mtDNA and mitochondrial transcription factors. Future studies should specifically target this residue using site-directed mutagenesis approaches (K622R to prevent succinylation or K622Q to mimic constitutive succinylation) .

• Cancer metabolism connections: SUCLG1-mediated POLRMT hyposuccinylation maintains mtDNA transcription, mitochondrial biogenesis, and leukemia cell proliferation. This suggests that researchers investigating cancer metabolism should incorporate SUCLG1 and protein succinylation into their experimental designs .

• Therapeutic targeting: The finding that genetic depletion of POLRMT or SUCLG1 significantly delays disease progression in mouse and humanized leukemia models suggests new therapeutic avenues. Research approaches should now include screening for compounds that modulate SUCLG1 activity or POLRMT succinylation .

• Clinical sample analysis: Succinyl-CoA level and POLRMT succinylation are downregulated in FLT3-mutated clinical leukemia samples. Future studies should stratify patient samples based on mutation status and correlate with these metabolic parameters .

What are promising future directions for SUCLG1 antibody applications in mitochondrial disease research?

Several promising future directions for SUCLG1 antibody applications in mitochondrial disease research include:

• Single-cell analysis: Adapting SUCLG1 antibodies for single-cell proteomics or imaging mass cytometry could reveal cell-to-cell heterogeneity in SUCLG1 expression and mitochondrial function within tissues, particularly important in mosaic mitochondrial disorders.

• In vivo imaging: Developing SUCLG1 antibody-based probes for in vivo imaging could allow for non-invasive monitoring of mitochondrial status in animal models of disease.

• Expanded phenotypic spectrum: Recent discoveries of milder phenotypes associated with SUCLG1 mutations suggest that SUCLG1 antibodies could be used to screen for subtle alterations in protein expression or localization in patients with unexplained neurological or metabolic symptoms.

• Tissue-specific metabolism: Using SUCLG1 antibodies in conjunction with spatial transcriptomics could map the relationship between SUCLG1 expression and local metabolic environments in complex tissues, providing insights into tissue-specific manifestations of mitochondrial diseases.

• Therapeutic monitoring: As treatments for mitochondrial disorders advance, SUCLG1 antibodies could serve as biomarkers to monitor treatment efficacy, particularly for interventions targeting the TCA cycle or mitochondrial biogenesis.

• Aging research: Given the central role of mitochondria in aging, SUCLG1 antibodies could be employed to investigate how age-related changes in SUCLG1 expression or function contribute to declining mitochondrial performance across tissues.

How can researchers integrate SUCLG1 antibody-based techniques with other emerging technologies in metabolism research?

Integration of SUCLG1 antibody-based techniques with emerging technologies offers powerful new approaches for metabolism research:

• CRISPR-based screening with antibody validation:

  • Perform genome-wide CRISPR screens for factors affecting mitochondrial function

  • Validate hits by assessing effects on SUCLG1 expression, localization, and complex formation using antibodies

  • Correlate genetic perturbations with metabolic phenotypes

• Spatial metabolomics and proteomics integration:

  • Combine SUCLG1 immunohistochemistry with MALDI imaging mass spectrometry

  • Map the spatial distribution of both SUCLG1 protein and relevant metabolites (succinyl-CoA, succinate)

  • Identify microenvironments with altered metabolism in tissues

• Live-cell imaging of metabolic dynamics:

  • Develop SUCLG1 antibody-derived intrabodies or nanobodies

  • Use for real-time monitoring of SUCLG1 localization and dynamics

  • Combine with fluorescent metabolite sensors for simultaneous visualization of protein and metabolite changes

• Microfluidic single-cell proteomics:

  • Analyze SUCLG1 expression in individual cells using antibody-based microfluidic platforms

  • Correlate with single-cell metabolomic data

  • Identify rare cell populations with altered SUCLG1 expression or function

• Antibody-based proximity labeling:

  • Fuse SUCLG1 antibodies or antibody fragments to enzymes like APEX2 or TurboID

  • Map the proximal proteome of SUCLG1 in different cellular states

  • Identify novel interaction partners and regulatory mechanisms

• Multi-omics data integration:

  • Use SUCLG1 antibody-based proteomics as one layer in multi-omics studies

  • Integrate with transcriptomics, metabolomics, and epigenomics data

  • Develop computational models that predict how SUCLG1 functions within the broader metabolic network

These integrated approaches will provide a more comprehensive understanding of how SUCLG1 functions within the complex landscape of cellular metabolism and may reveal new therapeutic opportunities for mitochondrial disorders and cancer.